Science4Beauty raises $1.9M for needle-free "botox in a cream
What's the deal? Polish biotech Science4Beauty has closed a 7,000,000 PLN (roughly $1.9 million) early-stage round led by 4growth VCDealroom has a profile for this one. Try Dealroom → and Hard2beatDealroom has a profile for this one. Try Dealroom →, alongside angel investors. The startup makes skincare based on its patented technology for producing recombinant proteins.
What's the endgame? Science4Beauty designs, produces, and purifies bioactive proteins and peptides in its own genetic-engineering lab. Its flagship line, Miorelaxant Magic, uses a conotoxin molecule that mimics sea-snail venom to relax facial muscles and smooth wrinkles — a "botox in a cream" effect without needles.
Does it work? Clinical studies showed the product reduced wrinkle depth by up to 48%. The company says regular use extends the effect of botulinum toxin treatments by around 60 days, a selling point for aesthetic-medicine clinics.
What's the money for? The funding will scale operations and open distribution channels in key foreign markets. Chief executive officer Magdalena Janczewska said the pipeline reaches beyond skincare, into treatments for excessive sweating, rosacea, and microneedle patches.
By the numbers: Science4Beauty has launched five products and generated over 500,000 PLN in 2025 revenue without marketing spend. Earlier NCBRDealroom has a profile for this one. Try Dealroom → grant funding of more than 10 million PLN cut the project's technology risk, according to 4growth VC.
Why now? The round lands as the global anti-aging market is projected to grow from $56 billion in 2025 to $108 billion in 2033. The fastest-growing segment is evidence-based clean-biotech products offering a non-invasive alternative to traditional procedures.
The signal: The deal reflects a shift in how investors view biotech. "We are moving away from the well-worn pattern in which biotech is associated solely with classic drug discovery," Hard2beat said (translated from Polish), pointing to synthetic biology and protein engineering as a faster route to market. As a datapoint, the round sits in the bottom 41% of comparable deals by size — modest capital for a company betting on quick commercialisation.
Read more: mamstartup.pl
Image credit: Generated with Gemini
